Steven Prakken, MD
Psychiatry · Durham, NCNPI 1578586624
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.2%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Pfizer at 42.5% of the total. Reporting peaked in 2019 at $18,367 and has fallen 99.5% since, to $84 in 2025. Among psychiatry clinicians in NC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 195 payments — averaging $111.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$9K
- Eli Lilly$6K
- Biodelivery Sciences International, Inc.$3K
- AbbVie$512
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$468
- Collegium Pharmaceutical, Inc.$275
- plus $2K from 26 others
What the payments were for
- Consulting fees$12,39057%
- Speaking & faculty fees$3,23015%
- Travel & lodging$2,40311%
- Food & beverage$3,62017%
- Education$120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 15 | $9,212 |
| Eli Lilly | 6 | $6,084 |
| Biodelivery Sciences International, Inc. | 3 | $3,255 |
| AbbVie | 33 | $512 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 39 | $468 |
| Collegium Pharmaceutical, Inc. | 12 | $275 |
| Johnson & Johnson | 11 | $263 |
| Neurocrine Biosciences, Inc. | 12 | $230 |
| Lundbeck LLC | 9 | $228 |
| Alkermes, Inc. | 9 | $218 |
| Otsuka America Pharmaceutical, Inc. | 10 | $204 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $67 |
| Averitas Pharma Inc. | 2 | $60 |
| Corium, LLC | 3 | $59 |
| Indivior Inc. | 3 | $55 |
| Vanda Pharmaceuticals Inc. | 3 | $51 |
| Bausch Health US, LLC | 2 | $48 |
| Axsome Therapeutics, Inc. | 2 | $47 |
| Ironshore Pharmaceuticals Inc. | 2 | $42 |
| Idorsia Pharmaceuticals US Inc | 2 | $35 |
| Abbott | 1 | $28 |
| Tris Pharma Inc | 2 | $28 |
| Livanova USA, Inc. | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Noven Therapeutics, LLC | 1 | $20 |
| Neos Therapeutics, LP | 1 | $19 |
| Amgen | 1 | $19 |
| Sonex Health, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $17 |
| Lilly USA, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BELBUCA$3,230
How this compares
$21,655 in reported general payments places this provider in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucyntaTapentadol Hcl | 17 | $25,436 |
| OxycontinOxycodone Hcl | 15 | $23,516 |
| Oxymorphone Hcl ErOxymorphone Hcl | 12 | $13,147 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 11 | $8,744 |
| Oxycodone Hcl | 50 | $2,977 |
| Modafinil | 17 | $2,548 |
| Hydromorphone Hcl | 32 | $1,553 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 18 | $880 |
| Duloxetine Hcl | 43 | $850 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 20 | $849 |
| Buprenorphine Hcl | 12 | $719 |
| Methocarbamol | 13 | $714 |
| Pregabalin | 29 | $574 |
| Clonazepam | 30 | $475 |
| Morphine Sulfate | 18 | $473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Nucynta | $275 | $25,43617 claims |
| Indivior Inc.Suboxone | $55 | $8,74411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,108 psychiatry providers in North Carolina.
Other psychiatry in Durham
- Mark ReynoldsDurham$3.2M
- Steven SzaboDurham$360K
- Andrew KrystalDurham$234K
- Ranjan SudanDurham$81K
- Caleb WhitenackDurham$68K
- Paolo MannelliDurham$38K
- P DoraiswamyDurham$35K
- David JarrettDurham$28K
- Mustafa HusainDurham$20K
- Damon TweedyDurham$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.